An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis
Latest Information Update: 21 Sep 2021
Price :
$35 *
At a glance
- Drugs Voclosporin (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Proof of concept; Therapeutic Use
- Acronyms AURONA
- Sponsors Aurinia Pharmaceuticals
- 16 Jun 2020 Status changed from recruiting to discontinued.
- 22 Apr 2020 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.
- 22 Apr 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Dec 2020.